好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Vitamin D Status in Optic Neuritis - An Update
MS and Related Diseases
S10 - (-)
004
The optic nerve is commonly targeted in demyelinating disease, providing a model for assessment of anti-inflammatory and neuroprotective therapies. Vitamin D is a known ameliorator of inflammatory activity. In-vitro evidence suggests it may also be neuroprotective, an examinable possibility using optic neuritis and OCT, in which degeneration is seen as early as 6 months.
Fifty patients with acute optic neuritis will undergo OCT testing to measure RFNL, macular volume and inter-eye RFNL difference, neurological examination and 25(OH)D testing at onset and month 6. Comparisons are made on OCT measures between vitamin D sufficient and insufficient patients at these times.
Currently 36 of 50 patients have been enrolled; 25 having completed the 6 month study. Twenty-four patients were vitamin D insufficient and 12 sufficient (mean 25(OH)D 60 nmol/L and 105 nmol/L respectively). Gender, age, disease category and steroid treatment did not differ between groups. Acutely, vitamin D insufficiency was associated with greater RFNL edema (136 vs 98 [micro]m, p=0.052) and macular volume (10.3 vs 9.8 mm3, p=0.032). At 6 months, mean inter-eye RFNL difference (IED) was 12 vs 2 [micro]m in vitamin D insufficient vs sufficient patients.
Results thus far show optic neuritis in the context of vitamin D insufficiency is associated with greater optic nerve structure edema acutely, and a greater degree of RFNL thinning (as measured by IED) at 6 months. These results suggest that vitamin D may be protective against both inflammatory and degenerative effects of demyelination.
Authors/Disclosures
Jodie Burton, MD, FAAN
PRESENTER 		Dr. Burton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Burton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Burton has received personal compensation in the range of $0-$499 for serving as a Consultant for Horizon. The institution of Dr. Burton has received research support from Roy and Joan Allen Professorship for Sight. Dr. Burton has a non-compensated relationship as a Advisor with CADTH that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Alexion that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Horizon that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a 好色先生al Chair with EMD Serono that is relevant to AAN interests or activities.
David C. Spencer, MD, FAAN Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuiticals. Dr. Spencer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace Inc. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various. The institution of Dr. Spencer has received research support from NIH. Dr. Spencer has received publishing royalties from a publication relating to health care. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Faculty in Teaching Course supported by unrestricted educational grants with Creative 好色先生 Concepts.
No disclosure on file
No disclosure on file
No disclosure on file
Fiona E. Costello, MD (Fiona Costello Professional Corporation) Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.